Literature DB >> 19404652

Pathology and new players in the pathogenesis of brain edema.

Sukriti Nag1, Janet L Manias, Duncan J Stewart.   

Abstract

Brain edema continues to be a major cause of mortality after diverse types of brain pathologies such as major cerebral infarcts, hemorrhages, trauma, infections and tumors. The classification of edema into vasogenic, cytotoxic, hydrocephalic and osmotic has stood the test of time although it is recognized that in most clinical situations there is a combination of different types of edema during the course of the disease. Basic information about the types of edema is provided for better understanding of the expression pattern of some of the newer molecules implicated in the pathogenesis of brain edema. These molecules include the aquaporins, matrix metalloproteinases and growth factors such as vascular endothelial growth factors A and B and the angiopoietins. The potential of these agents in the treatment of edema is discussed. Since many molecules are involved in the pathogenesis of brain edema, effective treatment cannot be achieved by a single agent but will require the administration of a "magic bullet" containing a variety of agents released at different times during the course of edema in order to be successful.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19404652     DOI: 10.1007/s00401-009-0541-0

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  71 in total

1.  Ghrelin prevents disruption of the blood-brain barrier after traumatic brain injury.

Authors:  Nicole E Lopez; Michael J Krzyzaniak; Chelsea Blow; James Putnam; Yan Ortiz-Pomales; Ann-Marie Hageny; Brian Eliceiri; Raul Coimbra; Vishal Bansal
Journal:  J Neurotrauma       Date:  2011-10-26       Impact factor: 5.269

Review 2.  Neuroinflammation: a common pathway in CNS diseases as mediated at the blood-brain barrier.

Authors:  Michelle A Erickson; Kenji Dohi; William A Banks
Journal:  Neuroimmunomodulation       Date:  2012-01-11       Impact factor: 2.492

3.  Treatment with Isorhamnetin Protects the Brain Against Ischemic Injury in Mice.

Authors:  Jin-Jing Zhao; Jin-Qing Song; Shu-Yi Pan; Kai Wang
Journal:  Neurochem Res       Date:  2016-05-09       Impact factor: 3.996

Review 4.  Neuroinflammatory imaging biomarkers: relevance to multiple sclerosis and its therapy.

Authors:  Thomas Tourdias; Vincent Dousset
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

5.  Soluble Epoxide Hydrolase in Hydrocephalus, Cerebral Edema, and Vascular Inflammation After Subarachnoid Hemorrhage.

Authors:  Dominic A Siler; Yosef A Berlow; Ayaka Kukino; Catherine M Davis; Jonathan W Nelson; Marjorie R Grafe; Hirohisa Ono; Justin S Cetas; Martin Pike; Nabil J Alkayed
Journal:  Stroke       Date:  2015-05-19       Impact factor: 7.914

6.  Blood brain barrier is impermeable to solutes and permeable to water after experimental pediatric cardiac arrest.

Authors:  Erika E Tress; Robert S B Clark; Lesley M Foley; Henry Alexander; Robert W Hickey; Tomas Drabek; Patrick M Kochanek; Mioara D Manole
Journal:  Neurosci Lett       Date:  2014-06-14       Impact factor: 3.046

7.  Limb Ischemic Perconditioning Attenuates Blood-Brain Barrier Disruption by Inhibiting Activity of MMP-9 and Occludin Degradation after Focal Cerebral Ischemia.

Authors:  Changhong Ren; Ning Li; Brian Wang; Yong Yang; Jinhuan Gao; Sijie Li; Yuchuan Ding; Kunlin Jin; Xunming Ji
Journal:  Aging Dis       Date:  2015-11-17       Impact factor: 6.745

Review 8.  Astrocytes: biology and pathology.

Authors:  Michael V Sofroniew; Harry V Vinters
Journal:  Acta Neuropathol       Date:  2009-12-10       Impact factor: 17.088

9.  Aquaporin and vascular diseases.

Authors:  Carla Loreto; Ester Reggio
Journal:  Curr Neuropharmacol       Date:  2010-06       Impact factor: 7.363

10.  Aquaporin and blood brain barrier.

Authors:  Francesca Bonomini; Bonomini Francesca; Rita Rezzani
Journal:  Curr Neuropharmacol       Date:  2010-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.